ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part I – assessment and management of various cardiovascular risk factors

Peritoneal Dialysis International

Volumn 35, Issue 4, 2015, Pages 379-387

  Moon Wang, Angela Yee ^a   Brimble, K Scott ^b   Brunier, Gillian ^c   Holt, Stephen G ^d   Jha, Vivekanand ^e   Johnson, David W ^f,g   Kang, Shin Wook ^h   Kooman, Jeroen P ⁱ   Lambie, Mark ^j   McIntyre, Chris ^k   Mehrotra, Rajnish ^l   Pecoits Filho, Roberto ^m  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^h Yonsei University   (South Korea)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j KEELE UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^l UNIVERSITY OF WASHINGTON   (United States)

^m PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

more..

Author keywords

Anemia; Cardiovascular risk; Dialysate calcium; Dyslipidemia; Glycosylated hemoglobin; Hypertension; Hypokalemia; Inflammation; Obesity; Peritoneal dialysis; Residual renal function; Salt; Volume

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE DEGRADATION PRODUCT; GLYCOSYLATED HEMOGLOBIN; ICODEXTRIN; UREA;

ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART VENTRICLE FIBRILLATION; HUMAN; HYDRATION; HYPERCALCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; INFLAMMATION; INTERNATIONAL SOCIETY FOR PERITONEAL DIALYSIS GUIDELINE; KIDNEY CLEARANCE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MORTALITY; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING; SODIUM RESTRICTION; ULTRAFILTRATION; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; FEMALE; MALE; MEDICAL SOCIETY; METABOLIC DISEASES; PATIENT SAFETY; RISK ASSESSMENT; STANDARDS; TREATMENT OUTCOME;

ADULT; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; METABOLIC DISEASES; PATIENT SAFETY; PERITONEAL DIALYSIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84938241417     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2014.00279     Document Type: Article

References (50)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012; 59:A7, el-420.
2. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302:1782-9.
3. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. KidneyInt 2006; 69:1726-32.
4. Holmes CJ. Glucotoxicity in peritoneal dialysis-solutions for the solution! Adv Chronic Kidney Dis 2007; 14:269-78.
5. Paniagua R, Ventura MD, Avila-Dfaz M, Hinojosa-Heredia H, Mendez-Duran A, Cueto-Manzano A, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010; 25:551-7.
6. Li PK, Culleton BF, Ariza A, Do JY, Johnson DW, Sanabria M, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013; 24:1889-900.
7. Hur E, Usta M, Toz H, Asci G, Wabel P, Kahvecioglu S, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 2013; 61:957-65.
8. Onofriescu M, Hogas S, Voroneanu L, Apetrii M, Nistor I, Kanbay M, et al. Bioimpedance-guided fluid management in maintenance hemo-dialysis: a pilot randomized controlled trial. Am J Kidney Dis 2014; 64:111-8.
9. Tentori F, Elder SJ, Thumma J, Pisoni RL, Bommer J, Fissell RB, et al. Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes. Nephrol Dial Transplant 2010; 25:3050-62.
10. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011:CD003236.
11. Molsted S, Eidemak I, Sorensen HT, Kristensen JH. Five months of physical exercise in hemodialysis patients: effects on aerobic capacity, physical function and self-rated health. Nephron Clin Pract 2004; 96:c76-81.
12. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ 2013; 346:f1325.
13. McCausland FR, Waikar SS, Brunelli SM. Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int 2012; 82:204-11.
14. Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Ertiirk S, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60:767-76.
15. de Brito-Ashurst I, Perry L, Sanders TA, Thomas JE, Dobbie H, Varagunam M, et al. The role of salt intake and salt sensitivity in the management of hypertension in South Asian people with chronic kidney disease: a randomised controlled trial. Heart 2013; 99:1256-60.
16. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-52.
17. Braatvedt G, Rosie B, Bagg W, Collins J. Current and former smoking increases mortality in patients on peritoneal dialysis. N Z Med J 2006; 119:1-10.
18. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-20.
19. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200-6.
20. Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010; 25:2288-96.
21. Lubowitz H, Slatopolsky E, Shankel S, Rieselbach RE, Bricker NS. Glomeru-lar filtration rate. Determination in patients with chronic renal disease. JAMA 1967; 199:252-6.
22. Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lindsay RM. Cystatin C levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol 2009; 4:1606-10.
23. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis. Lancet 2005; 366:2026-33.
24. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139:105-12.
25. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43:1056-64.
26. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097-107.
27. Cho Y, Johnson, DW, Craig, JC, Strippoli, GF, Badve, SV, Wiggins, KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2014; 3:CD007554.
28. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, et al.; EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephro 2003; 14:2948-57.
29. Qi H, Xu C, Yan H, Ma J. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int 2011; 31:179-88.
30. Cho Y, Johnson DW, Badve S, Craig JC, Strippoli GF, Wiggins KJ. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2013; 28:1899-907.
31. American Diabetes A. Standards of medical care in diabetes—2013. Diabetes Care 2013; 36(Suppl 1):S11-66.
32. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease: Chapter 3: Management of progression and complications of CKD. Kidney Int Suppl 2013; (3):S73-90.
33. American Diabetes A. Standards of medical care in diabetes—2014. Diabetes Care 2014; 37(Suppl 1):S14-80.
34. Han SS, Ahn JM, Chin HJ, Chae DW, Oh KH, Joo KW, et al. Impact of C-reactive protein and pulse pressure evaluated at the start of peritoneal dialysis on cardiovascular events in the course of treatment with peritoneal dialysis. Perit Dial Int 2010; 30:300-10.
35. Liu SH, Li YJ, Wu HH, Lee CC, Lin CY, Weng CH, et al. High-sensitivity C-reactive protein predicts mortality and technique failure in peritoneal dialysis patients. PLoS One 2014; 9, e93063.
36. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871-9.
37. Cengiz MI, Bal S, Gokgay S, Cengiz K. Does periodontal disease reflect atherosclerosis in continuous ambulatory peritoneal dialysis patients? J Periodontol 2007; 78:1926-34.
38. Cocchi R, Degli Esposti E, Fabbri A, Lucatello A, Sturani A, Quarello F, et al. Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study. Nephrol Dial Transplant 1999; 14:1536-40.
39. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant 2002; 17:1661-6.
40. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Stevens P, Krediet RT. Dialysis in the Netherlands: the clinical condition of new patients put into a European perspective. NECOSAD Study Group. Netherlands Cooperative Study on the Adequacy of Dialysis phase 1. Nephrol Dial Transplant 1999; 14:2438-44.
41. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005; 20:1693-701.
42. Udayaraj UP, Steenkamp R, Caskey FJ, Rogers C, Nitsch D, Ansell D, et al. Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 2009; 53:70-8.
43. Wang X, Axelsson J, Lindholm B, Wang T. Volume status and blood pressure in continuous ambulatory peritoneal dialysis patients. Blood Purif2005; 23:373-8.
44. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-27.
45. Weinreich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. Am J Kidney Dis 1995; 25:452-60.
46. Weinreich T, Ritz E, Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Perit Dial Int 1996; 16:260-8.
47. Osadchii, OE. Mechanisms of hypokalemia-induced ventricular arrhyth-mogenicity. Fundamental & Clin Pharmacol 2010; 24: 547-59.
48. McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med 2014; 15:11-23.
49. Szeto CC, Chow KM, Kwan BC, Leung CB, Chung KY, Law MC, et al. Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication. Am J Kidney Dis 2005; 46:128-35.
50. Torlen K, Kalantar-Zadeh K, Molnar MZ, Vashistha T, Mehrotra R. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol 2012; 7:1272-84.